167 related articles for article (PubMed ID: 37156422)
1. Perceived access to opioid agonist treatment in prison among people with a history of injection drug use: A qualitative study.
Marshall AD; Schroeder SE; Lafferty L; Drysdale K; Baldry E; Stoové M; Dietze P; Higgs P; Treloar C
J Subst Use Addict Treat; 2023 Jul; 150():209066. PubMed ID: 37156422
[TBL] [Abstract][Full Text] [Related]
2. Prospective study of retention in opioid agonist treatment and contact with emergency healthcare following release from prisons in Victoria, Australia.
Curtis M; Wilkinson AL; Dietze P; Stewart AC; Kinner SA; Cossar RD; Nehme E; Aitken C; Walker S; Butler T; Winter RJ; Smith K; Stoove M
Emerg Med J; 2023 May; 40(5):347-354. PubMed ID: 36759173
[TBL] [Abstract][Full Text] [Related]
3. Perspectives of clients and providers on factors influencing opioid agonist treatment uptake among HIV-positive people who use drugs in Indonesia, Ukraine, and Vietnam: HPTN 074 study.
Kiriazova T; Go VF; Hershow RB; Hamilton EL; Sarasvita R; Bui Q; Lancaster KE; Dumchev K; Hoffman IF; Miller WC; Latkin CA
Harm Reduct J; 2020 Oct; 17(1):69. PubMed ID: 32998731
[TBL] [Abstract][Full Text] [Related]
4. Determinants of willingness to enroll in opioid agonist treatment among opioid dependent people who inject drugs in Ukraine.
Makarenko I; Mazhnaya A; Polonsky M; Marcus R; Bojko MJ; Filippovych S; Springer S; Dvoriak S; Altice FL
Drug Alcohol Depend; 2016 Aug; 165():213-20. PubMed ID: 27370527
[TBL] [Abstract][Full Text] [Related]
5. Structural competency in the post-prison period for people who inject drugs: A qualitative case study.
Treloar C; Schroeder S; Lafferty L; Marshall A; Drysdale K; Higgs P; Baldry E; Stoove M; Dietze P
Int J Drug Policy; 2021 Sep; 95():103261. PubMed ID: 33990057
[TBL] [Abstract][Full Text] [Related]
6. Incidence and factors associated with discontinuation of opioid agonist therapy among people who inject drugs in Australia.
Geddes L; Iversen J; Wand H; Maher L
Addiction; 2021 Mar; 116(3):525-535. PubMed ID: 32557931
[TBL] [Abstract][Full Text] [Related]
7. Utilization of buprenorphine and methadone among opioid users who inject drugs.
Tsui JI; Burt R; Thiede H; Glick SN
Subst Abus; 2018 Jan; 39(1):83-88. PubMed ID: 28796591
[TBL] [Abstract][Full Text] [Related]
8. Discontinuation of opioid agonist treatment following release from prison in a cohort of men who injected drugs prior to imprisonment in Victoria, Australia: A discrete-time survival analysis.
Curtis M; Dietze P; Wilkinson AL; Agius PA; Stewart AC; Cossar RD; Butler T; Walker S; Kirwan A; Winter RJ; Stoové M
Drug Alcohol Depend; 2023 Jan; 242():109730. PubMed ID: 36516552
[TBL] [Abstract][Full Text] [Related]
9. Is use of opioid agonist treatment associated with broader primary healthcare use among men with recent injecting drug use histories following release from prison? A prospective cohort study.
Curtis M; Wilkinson AL; Dietze P; Stewart AC; Kinner SA; Winter RJ; Aitken C; Walker SJ; Cossar RD; Butler T; Stoové M
Harm Reduct J; 2023 Mar; 20(1):42. PubMed ID: 36978089
[TBL] [Abstract][Full Text] [Related]
10. Methadone within prison and linkage to and retention in treatment upon community release for people with opioid use disorder in Kyrgyzstan: Evaluation of a national program.
Bachireddy C; Shrestha R; Bromberg DJ; Azbel L; Kurmanalieva A; Wegman M; Shumskaya N; Rozanova J; Meyer JP; Altice FL
Int J Drug Policy; 2022 Mar; 101():103558. PubMed ID: 34915426
[TBL] [Abstract][Full Text] [Related]
11. Modelling the intervention effect of opioid agonist treatment on multiple mortality outcomes in people who inject drugs: a three-setting analysis.
Stone J; Degenhardt L; Grebely J; Larney S; Altice FL; Smyrnov P; Rahimi-Movaghar A; Alavi M; Young AM; Havens JR; Miller WC; Hickman M; Vickerman P
Lancet Psychiatry; 2021 Apr; 8(4):301-309. PubMed ID: 33640039
[TBL] [Abstract][Full Text] [Related]
12. Modeling the population-level impact of opioid agonist treatment on mortality among people accessing treatment between 2001 and 2020 in New South Wales, Australia.
Chaillon A; Bharat C; Stone J; Jones N; Degenhardt L; Larney S; Farrell M; Vickerman P; Hickman M; Martin NK; Bórquez A
Addiction; 2022 May; 117(5):1338-1352. PubMed ID: 34729841
[TBL] [Abstract][Full Text] [Related]
13. Acceptability of prison-based take-home naloxone programmes among a cohort of incarcerated men with a history of regular injecting drug use.
Curtis M; Dietze P; Aitken C; Kirwan A; Kinner SA; Butler T; Stoové M
Harm Reduct J; 2018 Sep; 15(1):48. PubMed ID: 30241532
[TBL] [Abstract][Full Text] [Related]
14. Within-prison drug injection among HIV-infected male prisoners in Indonesia: a highly constrained choice.
Culbert GJ; Waluyo A; Iriyanti M; Muchransyah AP; Kamarulzaman A; Altice FL
Drug Alcohol Depend; 2015 Apr; 149():71-9. PubMed ID: 25659895
[TBL] [Abstract][Full Text] [Related]
15. Impact of prerelease methadone on mortality among people with HIV and opioid use disorder after prison release: results from a randomized and participant choice open-label trial in Malaysia.
Bazazi AR; Culbert GJ; Wegman MP; Heimer R; Kamarulzaman A; Altice FL
BMC Infect Dis; 2022 Nov; 22(1):837. PubMed ID: 36368939
[TBL] [Abstract][Full Text] [Related]
16. Barriers to retention in methadone maintenance therapy among people who inject drugs in Bangkok, Thailand: a mixed-methods study.
Hayashi K; Ti L; Ayutthaya PPN; Suwannawong P; Kaplan K; Small W; Kerr T
Harm Reduct J; 2017 Sep; 14(1):63. PubMed ID: 28882155
[TBL] [Abstract][Full Text] [Related]
17. A social ecological model (SEM) to exploring barriers of and facilitators to the implementation of opioid agonist treatment (OAT) programmes in prisons.
Komalasari R; Wilson S; Haw S
Int J Prison Health; 2021 Nov; 17(4):477-496. PubMed ID: 38902897
[TBL] [Abstract][Full Text] [Related]
18. The Prison and Transition Health (PATH) Cohort Study: Study Protocol and Baseline Characteristics of a Cohort of Men with a History of Injecting Drug Use Leaving Prison in Australia.
Kirwan A; Curtis M; Dietze P; Aitken C; Woods E; Walker S; Kinner S; Ogloff J; Butler T; Stoové M
J Urban Health; 2019 Jun; 96(3):400-410. PubMed ID: 30989484
[TBL] [Abstract][Full Text] [Related]
19. Incidence of hepatitis C virus infection in the prison setting: The SToP-C study.
Hajarizadeh B; Carson JM; Byrne M; Grebely J; Cunningham E; Amin J; Vickerman P; Martin NK; Treloar C; Martinello M; Lloyd AR; Dore GJ;
J Viral Hepat; 2024 Jan; 31(1):21-34. PubMed ID: 37936544
[TBL] [Abstract][Full Text] [Related]
20. Effects of the Connections program on return-to-custody, mortality and treatment uptake among people with a history of opioid use: Retrospective cohort study in an Australian prison system.
Sullivan E; Zeki R; Ward S; Sherwood J; Remond M; Chang S; Kypri K; Brown J
Addiction; 2024 Jan; 119(1):169-179. PubMed ID: 37726971
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
